Lupin and Novartis resolve patent dispute over hypertension drug
Sep 16, 2009 (Datamonitor via COMTEX) --
Company: Novartis AG (NVS)
Indian pharmaceutical company Lupin and Swiss pharmaceutical group Novartis have reached an out-of court settlement over Novartis's hypertension drug sold under the brand name Lotrel, reported The Economic Times.
According to the news source, the settlement allows Lupin to launch a generic version of the drug ahead of its patent expiry in 2017 and get a one-time revenue upside.
Lupin intends to launch its generic version of Lotrel, a combination of amlodipine besylate and benazepril hydrochloride, within the next few years.
Lupin develops and markets a range of generic formulations and active pharmaceutical ingredients globally.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon
Copyright (C) 2009 Datamonitor. All rights reserved
News Provided by COMTEX
Company: Novartis AG (NVS)
Related terms: patent, pharmaceuticals, revenue
